Alnylam Presents Pre-Clinical Data on ALN-TTR for the Treatment of Transthyretin-Mediated Amyloidosis

News   Nov 03, 2009

 
Alnylam Presents Pre-Clinical Data on ALN-TTR for the Treatment of Transthyretin-Mediated Amyloidosis
 
 
 

RELATED ARTICLES

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

News

New programs added in respiratory and cardio-metabolic diseases.

READ MORE

Protein Acts as Brake on Learning and Memory

News

Researchers have discovered a new way that the protein RGS14 functions as a molecular brake on learning and memory

READ MORE

Lunaphore and Vitro Sign Collaboration Agreement

News

Companies announce a collaboration agreement to develop In Situ Hybridization (ISH) protocols for RNA and DNA targets in tissue using reagents provided by Vitro on Lunaphore’s rapid autostaining platform.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy